Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial

Abstract

Background As survival among patients with cystic fibrosis has improved in recent decades, complications have become increasingly relevant. The most frequent complication is cystic-fibrosis-related diabetes. The recommended treatment is injected insulin, but some patients are treated with oral antidiabetic drugs to ease the treatment burden. We assessed the efficacy and safety of oral antidiabetic drugs.Methods We did a multicentre, open-label, comparative, randomised trial in 49 centres in Austria, France, Germany, and Italy. Eligible patients had cystic fibrosis, were older than 10 years, and had newly diagnosed diabetes. We used a central randomisation schedule derived from a Geigy random number table to assign patients 1:1 to receive insulin or repaglinide, stratified by sex and age (10-15 years or >15 years). The primary outcome was glycaemic control assessed by mean change in HbA 1c concentration from baseline after 24 months of treatment. Differences between groups were assessed by linear models. The primary and safety analyses were done in the modified intention-to-treat population (including patients who stopped treatment early because of lack of efficacy). This trial is registered with ClinicalTrials.gov, number NCT00662714.Findings We enrolled 34 patients in the repaglinide group and 41 in the insulin group, of whom 30 and 37, respectively, were included in the analyses. At 24 months, glycaemic control was similar in the repaglinide and insulin groups (mean change in HbA 1c concentration from baseline 0·2% [SD 0·7%], 1·7 mmol/mol [8·1 mmol/mol] with repaglinide vs -0·2% [1·3%], -2·7 mmol/mol, [14·5 mmol/mol] with insulin; mean difference between groups -0·4%, (95% CI -1·1 to 0·2 [-4·4 mmol/mol, -11·5 to 2·7], p=0·15). The most frequent adverse events were pulmonary events (43 [40%] of 107 in the repaglinide group and 60 [45%] of 133 in the insulin group), and the most frequent serious adverse events were pulmonary events leading to hospital admission (five [50%] of ten and seven [54%] of 13, respectively).Interpretation Repaglinide for glycaemic control in patients with cystic-fibrosis-related diabetes is as efficacious and safe as insulin.Funding Mukoviszidose eV, Vaincre la Mucoviscidose, ABCF Association, and Novo Nordisk.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(17)30400-x

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

See all 71

Metadata

Authors
Ballmann, M., Hubert, D., Assael, B. M., Staab, D., Hebestreit, A., Naehrlich, L., Nickolay, T., Prinz, N., Holl, R. W., Staden, U., Claßen, M., Schuster, A., Mellies, U., Posselt, H.-G., Wiebel, M., Rietschel, E., Stern, M., Teschler, H., Smaczny, C., Köhnlein, T., Wienhausen-Wilke, V., Claaß, A., Biedermann, T., Dockter, G., Köster, H., Hebestreit, H., Ballke, E.-H., Heuer, H.-E., Kamin, W., Küster, P., Szczepanski, R., Keller, K.-M., Generlich, H., Bresser, H.-G., Kopp, M., Herting, E., Feickert, H.-J., Hautz, J., Schilling, B., Meyer, E., Mall, M. A., Wiebicke, W., Tegtmeyer, F.-K., Honer, M., Mosnier-Pudar, H., Lenoir, G., Robert, J.-J., Kessler, L., Weiss, L., Nove-Josserand, R., Vantyghem, M.-C., Munck, A., Wizla, N., Leroy, S., Loeuille, G.-A., Serreau, R., Aissat, F., Thalhammer, G. H., Huttegger, I., Eichler, I., & Götz, M.
Affiliations
  • Medizinische Hochschule Hannover (DE)
  • Sorbonne Paris Cité (FR)
  • University of Milan (IT)
  • Humboldt-Universität zu Berlin (DE)
  • University of Würzburg (DE)
  • Justus-Liebig-Universität Gießen (DE)
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
  • Universität Ulm (DE)
Corresponding author
Ballmann, Manfred
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2018-02
Volume
6
Issue
2
Pages
114-121
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2775772713
Cited by
71
References
31
Citations by year
2026: 7 · 2025: 5 · 2024: 6 · 2023: 9 · 2022: 10 · 2021: 9 · 2020: 8 · 2019: 7 · 2018: 9
FWCI
5.65
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Universität Ulm
  • Association Vaincre la Mucoviscidose
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
repaglinide, insulin, cystic fibrosis-related diabetes, cystic fibrosis, newly diagnosed diabetes, oral antidiabetic drugs, glycemic control, HbA1c, pulmonary exacerbations, adverse events, treatment burden, adolescents and adults, type 2 diabetes treatment, drug safety and efficacy comparison, hospitalization, hospital readmission
MeSH terms
Adolescent, Adult, Blood Glucose, Carbamates, Child, Cystic Fibrosis, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Piperidines, Prognosis, Biomarkers, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. https://app.cochat.ai/papers/10.1016/s2213-8587(17)30400-x
The paper
Ballmann, M., Hubert, D., Assael, B. M., Staab, D., Hebestreit, A., Naehrlich, L., Nickolay, T., Prinz, N., Holl, R. W., Staden, U., Claßen, M., Schuster, A., Mellies, U., Posselt, H.-G., Wiebel, M., Rietschel, E., Stern, M., Teschler, H., Smaczny, C., . . . Götz, M. (2018). Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(17)30400-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.